Charles Schwab Investment Management Inc. Buys 13,302 Shares of Bausch + Lomb Co. (NYSE:BLCO)

Charles Schwab Investment Management Inc. increased its stake in shares of Bausch + Lomb Co. (NYSE:BLCO) by 80.8% in the third quarter, HoldingsChannel reports. The firm owned 29,755 shares of the company’s stock after buying an additional 13,302 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Bausch + Lomb were worth $576,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in BLCO. Blue Trust Inc. lifted its position in shares of Bausch + Lomb by 14,052.2% during the second quarter. Blue Trust Inc. now owns 3,255 shares of the company’s stock valued at $47,000 after buying an additional 3,232 shares during the last quarter. Renaissance Capital LLC boosted its position in shares of Bausch + Lomb by 20.0% in the 3rd quarter. Renaissance Capital LLC now owns 43,560 shares of the company’s stock worth $840,000 after purchasing an additional 7,274 shares in the last quarter. Squarepoint Ops LLC purchased a new position in Bausch + Lomb during the 2nd quarter worth $173,000. Fore Capital LLC increased its position in Bausch + Lomb by 90.2% during the 2nd quarter. Fore Capital LLC now owns 42,180 shares of the company’s stock valued at $612,000 after buying an additional 20,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Bausch + Lomb by 53.9% in the second quarter. Dimensional Fund Advisors LP now owns 67,690 shares of the company’s stock valued at $984,000 after buying an additional 23,714 shares during the last quarter. Institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Stock Down 3.2 %

Shares of BLCO opened at $18.24 on Thursday. The company has a current ratio of 1.57, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. The firm has a market cap of $6.42 billion, a P/E ratio of -17.37, a PEG ratio of 1.74 and a beta of 0.43. The stock’s 50 day moving average is $19.86 and its two-hundred day moving average is $17.58. Bausch + Lomb Co. has a 12 month low of $13.16 and a 12 month high of $21.69.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.16 by $0.01. The company had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The firm’s revenue was up 18.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.22 EPS. Analysts predict that Bausch + Lomb Co. will post 0.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BLCO has been the topic of several recent analyst reports. Royal Bank of Canada upped their price objective on shares of Bausch + Lomb from $20.00 to $23.00 and gave the company an “outperform” rating in a report on Tuesday, October 22nd. Citigroup downgraded shares of Bausch + Lomb from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $24.00 to $22.00 in a research note on Wednesday, December 11th. Bank of America reissued an “underperform” rating and issued a $18.00 target price on shares of Bausch + Lomb in a research report on Thursday, December 12th. Stifel Nicolaus lifted their price target on Bausch + Lomb from $16.00 to $19.00 and gave the stock a “hold” rating in a research report on Monday, September 23rd. Finally, Evercore ISI upgraded Bausch + Lomb from an “in-line” rating to an “outperform” rating and boosted their price target for the company from $19.00 to $25.00 in a research note on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $20.58.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.